focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 22.50
Bid: 22.00
Ask: 23.00
Change: -0.75 (-3.23%)
Spread: 1.00 (4.545%)
Open: 24.25
High: 24.50
Low: 22.50
Prev. Close: 23.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS SUMMARY: Angle revenue up; Synairgen, Bango loss widens

Thu, 29th Sep 2022 20:30

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Angle PLC - Surrey, England-based medical diagnostics company - Pretax loss in the first half of 2022 widens to GBP10.5 million from GBP8.7 million, due to "a planned investment." Revenue rises to GBP419,000 from GBP296,000, "driven by research use sales of the Parsortix system along with an initial contribution from the pharma services business, including both clinical trial services and bespoke assay development." Expects its first FDA clearance to "positively impact all areas" of its business going forward.

----------

Bango PLC - Cambridge-based mobile commerce company - Pretax loss widens to USD1.2 million in the first half of 2022 from USD617,000 a year before. Administrative expenses rise to USD10.4 million from USD9.2 million. Revenue grows to USD10.8 million versus USD9.9 million. Attributes this to its "virtuous circle strategy" and investment in research and development, which continues to generate strong growth. Believes it is well positioned to continue taking market share.

----------

XLMedia PLC - Henley-on-Thames-based digital publisher - Pretax loss widens to USD1.7 million in the first half of 2022 from USD439,000 a year ago. Sales and marketing costs jump to USD16.2 million from USD7.3 million. Revenue rises 48% to USD44.5 million from USD32.2 million. Attributes this to new partnerships throughout the period. Expects full-year adjusted earnings before interest, tax, depreciation, and amortization is broadly in line with the prior year, returning to growth in 2023.

----------

Maintel Holdings PLC - London-based cloud and managed service specialist - Pretax loss in the six months to June 30 dives to GBP575,000 from a profit of GBP3.8 million a year before. Revenue falls 13% to GBP46.7 million from GBP53.5 million. Blames this on hardware supply-chain problems that significantly hurt revenue. Notes that supply chains are not expected to normalise until the second quarter of 2023. Remains confident that it will return to organic growth as global supply chains normalise.

----------

Synairgen PLC - Southampton, England-based drug discovery and biotechnology company - Pretax loss for the half-year to June 30 shrinks to GBP14.0 million from GBP38.9 million, as research and development expenditure falls to GBP11.1 million from GBP36.9 million. Explains that expenditure on the phase 3 Sprinter trial and manufacturing activities reduced.

----------

Armadale Capital PLC - London-based Africa-focused natural resource projects investor - Pretax loss in the first half of 2022 widens to GBP152,000 from GBP27,000 a year before. Records an unrepeated gain of GBP139,000 in the prior period.

----------

Arc Minerals Ltd - base metals exploration company focused in Africa - Pretax loss in the first half widens to GBP8.5 million from GBP3.6 million a year before. Attributes this to an expense of GBP6.8 million, due to the Zamsort/Handa restructuring, after transferring Zamsort assets and liabilities to Handa Resources Ltd.

----------

Orosur Mining Inc - Toronto-based mineral exploration & development company focused on South America - Net loss for continued operations in the year to May 31 narrows to USD1.4 million from USD1.7 million a year before. Gain on fair value of warrants increases to USD1.6 million from USD627,000. "The handing over of operational control at Anza in late 2021, and a strong balance sheet, have freed up our skilled South American team to examine investment in new projects. The addition of our Ariquemes tin project in Brazil, and of the El Pantano gold/silver project in Argentina have transformed the company into a well-balanced minerals exploration company," Executive Louis Castro comments.

----------

VPC Specialty Lending Investments PLC - invests in asset-backed loans to businesses originated by non-bank lenders - Net asset value as at June 30 falls to 105.51 pence from 114.14p as at December 31. Share price on the same date falls to 83.40p from 92.20p as at December 31. Delivers a total return of negative 4.1%. Blames this on an unpredictable and volatile macroeconomic environment. Declares quarterly dividends totalling 4.00 pence per share. Remains in a period of heightened uncertainty, with inflation still at "worryingly high levels".

----------

Crossword Cybersecurity PLC - Richmond, England-based cybersecurity solutions company - Pretax loss in the first half of 2022 widens to GBP2.3 million from GBP1.5 million a year before. Administrative expenses grow to GBP2.1 million from GBP1.5 million. Revenue grows 85% to GBP1.5 million versus GBP824,923. Attributes this to the integration of three companies with strong underlying Software as a service and services recurring revenue. Projects revenue growth of roughly 75% to GBP4 million in 2022, driven by organic growth and already completed acquisitions.

----------

By Abby Amoakuh; abbyamoakuh@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
27 Feb 2020 12:42

Angle upbeat on recent Parsortix research out of Italy

(Sharecast News) - Liquid biopsy company Angle announced on Thursday that Istituto Nazionale Tumori di Milano in Milan, Italy, has published results of work assessing the performance of its 'Parsortix' system in renal cell carcinoma (RCC), demonstrating key advantages of Parsortix.

Read more
17 Feb 2020 15:25

Angle upbeat on German research into 'Parsortix'

(Sharecast News) - Liquid biopsy company Angle announced on Monday that University Medical Centre Hamburg-Eppendorf has published results of work undertaken to assess the analytical and clinical performance of 'Parsortix' in multiple metastatic cancer types, with the main emphasis on metastatic breast cancer.

Read more
11 Feb 2020 10:51

Study Finds Angle's Parsortix Can Predict Melanoma Sufferers Survival

Study Finds Angle's Parsortix Can Predict Melanoma Sufferers Survival

Read more
11 Feb 2020 07:41

Angle upbeat on research into Parsortix with melanoma patients

(Sharecast News) - Liquid biopsy company Angle announced on Tuesday that a customer, the Edith Cowan University in Perth, Western Australia, has published results of research into the use of its 'Parsortix' system with melanoma patients.

Read more
30 Jan 2020 11:41

Angle Loss Widens As It Eyes US Parsotix Cancer Treatment Clearance

Angle Loss Widens As It Eyes US Parsotix Cancer Treatment Clearance

Read more
23 Jan 2020 16:10

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
22 Jan 2020 11:00

Angle Eyes US Consent For Parsortix Cancer Medication In Third Quarter

Angle Eyes US Consent For Parsortix Cancer Medication In Third Quarter

Read more
7 Nov 2019 13:50

Angle Gets Study Results Demonstrating Use Of Parsortix In Melanoma

Angle Gets Study Results Demonstrating Use Of Parsortix In Melanoma

Read more
31 Oct 2019 15:38

Angle Submits Positive Test Results For Parsortix System To US FDA

Angle Submits Positive Test Results For Parsortix System To US FDA

Read more
4 Oct 2019 15:17

Angle upbeat on patent grant for prostate cancer blood assessment

(Sharecast News) - Liquid biopsy company Angle announced on Friday that the Queen Mary University of London (QMUL) European patent covering the measurement of the number of megakaryocytes in a patient blood sample as an assessment of the prognosis for prostate cancer has been granted.

Read more
4 Oct 2019 08:58

Angle Notes Queen Mary University's European Cancer Prognosis Patent

Angle Notes Queen Mary University's European Cancer Prognosis Patent

Read more
4 Sep 2019 14:09

Angle Reports Positive Study Results For Parsortix System

(Alliance News) - Angle PLC on Wednesday noted positive results from a study of its Parsortix system in small cell lung cancer.Parsortix is Angle's liquid biopsy technology, meaning it

Read more
29 Aug 2019 10:57

Angle Ovarian Cancer Testing Platform Study Enrols First Patients

(Alliance News) - Liquid biopsy firm Angle PLC said Thursday the first patients for its ovarian cancer test study have been enrolled ahead of anticipated completion early in 2020.The study

Read more
29 Aug 2019 09:12

Angle initiates main phase of ovarian cancer clinical study

(Sharecast News) - Liquid biopsy company Angle announced on Friday that the main phase of its 200-patient ovarian cancer clinical verification study has been initiated and the first patient has been enrolled.

Read more
22 Jul 2019 12:53

Angle's Parsortix Used For Analysis Of Circulating Tumor Cells

(Alliance News) - Angle PLC on Monday said one of its leading customers, the Disseminated Cancer Cell Network, has published new results of work done to develop a "robust, reliable and for of

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.